Published in
Elsevier, The Lancet, 10103(390), p. 1645-1653
DOI: 10.1016/s0140-6736(17)31442-3
Links
Tools
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
Journal article published in 2017 by
Martin J. van den Bent,
Brigitta Baumert,
Sara C. Erridge,
Michael A. Vogelbaum,
Anna K. Nowak,
Marc Sanson 
,
Alba Ariela Brandes,
Paul M. Clement,
Jean Francais Baurain,
Warren P. Mason,
Helen Wheeler,
Olivier L. Chinot ,
Sanjeev Gill,
Matthew Griffin,
David G. Brachman
and other authors.
,
Alba Ariela Brandes,
Paul M. Clement,
Jean Francais Baurain,
Warren P. Mason,
Helen Wheeler,
Olivier L. Chinot ,
Sanjeev Gill,
Matthew Griffin,
David G. Brachman
and other authors.
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-co-deleted anaplastic gliomas.